cUTI Roundtable: Discussing and diagnosing these difficult infections
This series looks to discuss several topics around these infections including diagnosis, treatment, challenges in managing UTIs in patients with dementia and neurogenic bladders, antibiotic resistance, and considerations for patients and caregiver engagement.
We want to welcome you to the first episode from our complicated UTI roundtable series, which is a collaborative effort that includes Contemporary Pediatrics, Contagion, and Contemporary OB/GYN. This series looks to discuss several topics around these infections including diagnosis, treatment, challenges in managing UTIs in patients with dementia and neurogenic bladders, antibiotic resistance, and considerations for patients and caregiver engagement.
Our panel of clinicians includes:
- Barbara Trautner, MD, PhD, professor, Infectious Diseases, Section of Health Services Research, Baylor College of Medicine
- Kimberly Claeys, PharmD, associate professor of Practice, Sciences, and Health Outcomes Research, University of Maryland Baltimore
- Laila Woc-Colburn, MD, associate professor, Division of Infectious Diseases, Emory University School of Medicine
This 3-part series that will be posted every Wednesday over the coming weeks. In today’s episode, the clinicians discuss what constitutes a complicated UTI and how does diagnosis and treatment differ between patient groups, such as men versus women, pregnant patients, or pediatric patients.
This roundtable is part of ongoing educational and informational multimedia series we are producing and for any feedback or suggestions, please feel free to email John Parkinson at jparkinson@mjhlifesciences.com.
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Tebipenem HBr cUTI trial ends early after meeting efficacy goals
May 28th 2025GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial for tebipenem HBr, a potential first oral carbapenem for cUTIs in the United States, was stopped early because of positive efficacy results.
Read More
